Eli Lilly is halting development of solanezumab after it failed to slow cognitive decline in a study of patients at risk of Alzheimer’s disease, the drugmaker said March 8.
Read the full post on Becker's Hospital Review - Healthcare News
Eli Lilly to halt development of Alzheimer's treatment candidate
